How Castagna was paid
$9.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Michael E. CastagnaChief Executive Officer | $789,436 | $7,689,480 | $675,757 | $145,812 | $9,300,485 |
| Christopher B. PrentissChief Financial Officer | $470,085 | $2,133,480 | $251,495 | $31,739 | $2,886,799 |
| Dominic MarascoPresident, Endocrine Business Unit | $447,596 | $6,269,015 | $239,464 | $24,397 | $6,980,472 |
| David B. ThomsonEVP, General Counsel and Secretary | $520,748 | $2,133,480 | $378,600 | $122,420 | $3,155,248 |
| Stuart A. TrossEVP, Human Resources | $438,709 | $2,133,480 | $234,709 | $138,797 | $2,945,695 |
What changed and why
- $9.3MMichael E. Castagna total compensation decreased to $9,300,485 in fiscal 2025 compared to $9,490,628 in 2024.
- 107.0%The Compensation Committee assessed corporate goal achievement at 107.0% for the year ended December 31, 2025.
- Long-term equity incentives emphasize performance-based vesting measured by relative TSR.
- 91%Approximately 91% of the votes cast supported the say-on-pay proposal in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.